Scioderm, Inc., an Amicus Therapeutics Company

Scioderm, Inc. is a Durham, North Carolina-based biotechnology company dedicated to developing innovative treatments for rare genetic diseases. As an Amicus Therapeutics Company, we focus on addressing unmet medical needs, particularly in the field of Epidermolysis Bullosa (EB). We are committed to advancing patient care through rigorous research and development, leveraging our expertise in drug delivery and formulation. Our work directly supports individuals and families impacted by EB, offering hope for improved quality of life.

Scioderm’s primary focus has been on the development of SD-101, an investigational topical treatment for EB. While the program was discontinued following Phase 3 clinical trial results, the valuable data and insights gained continue to inform our approach to rare disease therapies.

We operate as part of Amicus Therapeutics, a global biotechnology company, and collaborate with other organizations within the EB community to accelerate the discovery and delivery of transformative medicines. We are driven by a mission to improve the lives of patients with rare genetic conditions.